Allshares Accelerates Growth with New CEO, Innovation, and Market Expansion
Last year was a record year for Allshares, a European leader in equity and incentive solutions. After seeing success across its current markets, the company is now entering a new transformative phase of growth, reinforcing its position as an international leader in equity and incentive solutions. Through leadership expansion, strategic acquisitions, and innovation-driven initiatives, the company is scaling rapidly and shaping the future of the industry, positioning itself as a long-term market leader.
Fabio Ronga Appointed as CEO to Drive Continued Growth
Fabio Ronga joins Allshares from beqom, where he served as Chairman and CEO, helping to successfully scale the company into a leading global compensation management provider. Fabio brings a proven track record of growing SaaS companies, driving innovation, and shaping market leaders. His appointment marks a key milestone in Allshares’ accelerated global expansion.
Product Innovation Driving Market Leadership
Allshares has also introduced several product innovations to enhance user experience, establish market leadership, and maintain a competitive edge:
- New Incentive Plan ManagementInsights: Provides flexible incentive plans and detailed insights, helping businesses and employees understand the value and impact of their incentives throughout the plan’s lifetime.
- New Cap Table & Share Register Tool: Manages cap tables of varying complexities, offering a robust solution to meet evolving client needs and providing enhanced support for private companies.
- Enhanced Pay Analytics Platform: A more intuitive, user-friendly interface for seamless compensation analysis.
Expanding Reach Across Europe
Allshares has been executing on several exciting and aggressive expansion initiatives to further strengthen its European presence:
- Significant Growth in Norway: Following a successful 2024, Allshares expanded its customer base in Norway by 220%, including five enterprises listed on the OBX25.
- New Office in Norway: To support this rapid growth, Allshares has opened a new office in Oslo, strengthening its Nordic presence and reinforcing its commitment to serving local businesses.
- New Office in Switzerland: To further expand Allshares’ European presence, the company has opened an office in Nyon, marking another step in its growth strategy.
Reinforcing Thought Leadership
Allshares continues to shape the executive compensation landscape through research, insights, and industry engagement:
- Board Remuneration & Pay Reports: Offering data-driven insights for listed companies to benchmark and optimize board pay strategies.
- Survey on Incentive Plan Parameters in PE-Backed Companies: Analyzing equity pool sizes, vesting criteria, and incentive structures used by private equity firms.
- State of the Nordics Responsible Investing Report: A collaboration with Cevian Capital providing insights on integrating ESG metrics into executive compensation, aligning sustainability with long-term profitability.
Looking Ahead
“This is an exciting time to join Allshares at a pivotal moment of growth and innovation,” said Fabio Ronga, newly appointed CEO of Allshares. “The company is uniquely positioned to transform the equity management landscape, and I look forward to accelerating our geographic expansion, investing in innovation, and delivering even greater value to our clients.”
“With a strong leadership team, a commitment to innovation, and an expanding global presence, we are creating the next generation of Incentive plan management solutions to democratize equity ownership and drive business success,” added Cyrus Shey, Managing Partner at Bregal Milestone, Allshares’ private equity partner. “We are incredibly excited to welcome Fabio to the Allshares team and look forward to partnering as we work together to stay ahead of market trends and empower organizations with smarter, more sustainable solutions to help drive meaningful change in the compensation landscape.”
About Allshares
Allshares is a European leader in equity, incentive and compensation solutions, providing businesses with advanced software, advisory, and reporting tools. With a focus on innovation, Allshares helps organizations implement effective and sustainable compensation strategies that drive commercial success and improve employee retention. For further information, please visit www.allshares.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250318771377/en/
Contacts
For Allshares: press@allshares.com
For Bregal Milestone: jillian.hazelton@bregal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 23:32:00 EEST | Press release
Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management to fully concentrate on on-field performance, ensuring that collective focus remains on
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 21:00:00 EEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK ® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater restoration of CFTR function, is associated with improved outcomes in people with cystic fibrosis (CF). For all clinical outcomes in the study, SwCl levels below 60 mmol/L were associated with greater benefit
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10 th Anniversary Year of NAHYCO ® Technology6.6.2025 17:00:00 EEST | Press release
IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603094257/en/ IBSA’s stand at IMCAS Asia 2025 As part of the congress, IBSA Derma will host a scientific symposium titled “The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line” scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 15:00:00 EEST | Press release
HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison System remains in investigational use for kidney applications and is not yet FDA-approved for this indication. Data from the #H
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom